DEFM14A: SpringWorks Therapeutics to be Acquired by Merck KGaA for $47.00 Per Share in All-Cash Transaction

SpringWorks Therapeutics, Inc. has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $47.00 per share in cash, representing a 26% premium to its unaffected 20-day volume-weighted average price.

Summary

• SpringWorks Therapeutics, Inc. (the "Company") has entered into an Agreement and Plan of Merger, dated April 27, 2025, with Merck KGaA, Darmstadt, Germany ("Parent"), and EMD Holdings Merger Sub, Inc. ("Merger Sub").
• Pursuant to the Merger Agreement, Merger Sub will merge with and into SpringWorks, with SpringWorks surviving as a wholly owned subsidiary of Parent.
• SpringWorks stockholders will receive $47.00 in cash, without interest and less any applicable withholding taxes, for each Company Share they own.
• This merger consideration represents a 26% premium to SpringWorks' unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025, the day prior to the first market speculation of a potential transaction.
• A Special Meeting of stockholders will be held virtually on June 26, 2025, at 10:00 a.m. Eastern Time, to vote on the Merger Proposal, Adjournment Proposal, and Compensation Proposal.
• The Merger Proposal requires the affirmative vote of the holders of a majority of the issued and outstanding Company Shares as of the Record Date (May 27, 2025).
• The Board of Directors of SpringWorks unanimously recommends that stockholders vote FOR the Merger Proposal, FOR the Adjournment Proposal, and FOR the Compensation Proposal.
• If the Merger is consummated, SpringWorks' shares will be delisted from the Nasdaq Stock Market LLC and deregistered under the Securities Exchange Act of 1934.
• The Merger is currently anticipated to be consummated in the second half of 2025, subject to satisfaction or waiver of all conditions, including regulatory approvals.
• SpringWorks is a commercial-stage biopharmaceutical company with two approved products: OGSIVEO (nirogacestat) for desmoid tumors and GOMEKLI (mirdametinib) for neurofibromatosis type 1, and a pipeline of earlier-stage candidates.
• Parent (Merck KGaA) is a leading science and technology company with 2024 sales of €21.2 billion across life science, healthcare, and electronics.

Sentiment

Score: 8

Explanation: The document outlines a definitive merger agreement with a significant premium for shareholders, supported by fairness opinions from two financial advisors and a unanimous board recommendation. While there are standard risks associated with any merger and a termination fee, the overall tone and details suggest a favorable outcome for shareholders, providing immediate cash value and certainty. The slight reduction in offer price from $50 to $47 due to diligence findings and regulatory timing is noted but the board still views it as the best obtainable offer.

Positives

• The all-cash consideration of $47.00 per share provides immediate value and liquidity to SpringWorks stockholders.
• The merger consideration represents a significant premium of 26% over the unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025.
• The Board of Directors, after thorough review and consultation with financial and legal advisors, determined the Merger Agreement to be advisable, fair, and in the best interests of the Company and its stockholders.
• The Board concluded that the $47.00 per share consideration was the highest reasonably obtainable after arms-length negotiations.
• The Merger is not conditioned on Parent's receipt of financing, indicating high certainty of funds for the transaction.
• Regulatory approval from the Bundeskartellamt (German antitrust authority) was obtained on May 20, 2025.
• The Merger Agreement includes provisions designed to increase the likelihood of completing the Merger.
• Stockholders who object to the Merger and comply with specific procedures under Delaware law are entitled to statutory appraisal rights.

Negatives

• SpringWorks stockholders will no longer participate in any potential future growth or upside from the Company's standalone business plan.
• The Merger Agreement restricts SpringWorks from actively soliciting alternative acquisition proposals.
• A termination fee of $145,600,000 is payable by SpringWorks under certain circumstances, which could be a significant cost if the merger fails.
• The receipt of the all-cash merger consideration will be a taxable transaction for U.S. federal income tax purposes for U.S. Holders.
• If the Merger is not consummated, SpringWorks' stock price may decline significantly, potentially below its price prior to the public announcement of the Merger Agreement.
• The transaction involves significant costs, fees, and expenses for SpringWorks.
• The Merger Agreement imposes restrictions on SpringWorks' business activities prior to closing, potentially limiting its ability to pursue new opportunities.

Risks

• The Merger may not be consummated within the anticipated timeframe or at all, due to failure to obtain required stockholder approval or satisfy other closing conditions.
• Required regulatory approvals may delay the consummation of the Merger or result in the imposition of conditions that could lead to abandonment of the Merger.
• The Merger Agreement may be terminated in circumstances requiring SpringWorks to pay a termination fee of $145,600,000 to Parent.
• If the Merger is not consummated, SpringWorks' stock price may decline significantly, potentially below its price prior to the public announcement of the Merger Agreement.
• The announcement, pendency, or consummation of the Merger could adversely affect SpringWorks' business relationships (employees, suppliers, customers, partners) and its operating results and cash flows.
• The proposed Merger may disrupt SpringWorks' current plans and operations or affect its ability to retain or recruit key employees.
• Competitors may react negatively to the proposed Merger.
• Diversion of management and employee attention from ongoing business operations due to the proposed transaction.
• Restrictions on SpringWorks' business activities under the Merger Agreement may limit its ability to pursue certain business opportunities or alternatives during the pendency of the Merger.
• Potential litigation related to the Transactions could be instituted against SpringWorks or its directors and officers.
• SpringWorks is unable to solicit other Acquisition Proposals during the pendency of the Merger.
• Receipt of the all-cash Merger Consideration is taxable to U.S. Holders for U.S. federal income tax purposes.
• Risks related to the implementation of SpringWorks' business model and strategic plans for its commercial products and product candidates.
• Risks related to the advancement of product candidates into, and successful completion of, preclinical and clinical investigations, studies, or clinical trials.
• Risks and uncertainties related to regulatory application, review, and approval processes and SpringWorks' compliance with applicable legal and regulatory requirements.
• General industry conditions and competition could impact SpringWorks' business.
• Potential impact of general economic, political, and market factors on the parties to the proposed Merger.
• Negative or adverse regulatory actions, requests, recommendations, determinations, or decisions of the European Medicines Agency relating to European marketing authorizations, unless arising from undisclosed prior knowledge or fraud/misconduct, could be a risk.

Future Outlook

If the Merger is consummated, SpringWorks Therapeutics will cease to be a publicly traded company, becoming a wholly owned subsidiary of Merck KGaA, and its shares will be delisted from Nasdaq and deregistered from the SEC. This means existing stockholders will no longer have an ownership interest in SpringWorks. If the Merger is not consummated, SpringWorks will remain a public company, its shares will continue to be listed on Nasdaq, and it will continue to file periodic reports with the SEC, but its stock price may experience a significant decline.

Management Comments

• Saqib Islam, Chief Executive Officer, stated: 'On behalf of the Board, I thank you for your support and appreciate your consideration of this matter.'
• SpringWorks management conveyed to Party B that the Company was willing to consider an offer for only the nirogacestat business and encouraged diligence.
• Parent stated its commitment to completing a transaction expeditiously.
• Parent reiterated its commitment to a $50.00 per share price despite diligence findings that reduced Parent's view of nirogacestat's commercial potential in Europe, contingent on a positive CHMP Opinion.
• Parent's revised proposal of $47.00 per share was communicated as their 'last, best and final' offer.

Industry Context

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on precision medicine for rare diseases and cancer, with two approved products (OGSIVEO and GOMEKLI) and a pipeline of small molecule targeted oncology assets. Merck KGaA, Darmstadt, Germany, is a large, diversified science and technology company with significant operations in life science, healthcare, and electronics globally. This acquisition represents a strategic move by Merck KGaA to expand its healthcare portfolio, particularly in the high-growth areas of oncology and rare diseases, by integrating SpringWorks' approved products and development pipeline. The transaction reflects a broader industry trend of larger pharmaceutical companies acquiring smaller, innovative biotechs to bolster their product offerings and R&D capabilities, especially those with commercial-stage assets and a precision medicine approach. The document also highlights the competitive landscape by noting the Board's efforts to gauge interest from other strategic counterparties, none of whom expressed interest in a whole company acquisition at an acceptable price, reinforcing the strategic fit and value proposition of the Merck KGaA offer.

Comparison to Industry Standards

• Centerview's Selected Public Company Analysis compared SpringWorks to early commercial-stage biopharmaceutical companies, noting EV/2028E Revenue Trading Multiples for comparable companies ranged from 0.4x to 5.2x, with Centerview applying a reference range of 1.50x to 3.00x to SpringWorks' estimated 2028 risk-adjusted revenue.
• Centerview's Selected Precedent Transaction Analysis reviewed transactions involving public early commercial-stage biopharmaceutical companies with enterprise values between $3 billion and $7 billion, where TV/4-Year Forward Revenue Multiples ranged from 2.3x to 5.2x. Centerview applied a reference range of 2.25x to 4.00x.
• Goldman Sachs' Premia Paid Analysis, based on biopharmaceutical industry transactions from January 1, 2020, with target enterprise values between $3 billion and $7 billion, indicated a reference range of illustrative premiums of 27% to 122% to the undisturbed closing price.
• The Board considered the $145,600,000 termination fee to be reasonable relative to termination fees in transactions of a similar size, suggesting it aligns with industry norms for M&A agreements.

Corporate Governance

Legal Proceedings

• As of the date of the Merger Agreement, there are no pending or threatened material legal proceedings against SpringWorks or its subsidiaries, or any material outstanding orders.
• SpringWorks has not received any written communication from a Governmental Entity alleging or giving notice of violations of Anti-Corruption Laws, anti-money laundering laws, or similar effects.
• There are no pending or threatened proceedings against SpringWorks or its subsidiaries regarding the classification or misclassification of Company Employees.
• There are no claims or proceedings pending or threatened alleging product liability against SpringWorks or its subsidiaries.
• No actual or threatened enforcement actions by any Regulatory Agency against SpringWorks or its subsidiaries have been reported.
• SpringWorks has not received any FDA Form 483, notice of violation, warning letter, or other correspondence from any Regulatory Agency alleging material noncompliance with Healthcare Laws or Licenses.
• No officers, employees, or agents of SpringWorks have engaged in conduct that would result in debarment or exclusion by regulatory bodies.
• SpringWorks is not a party to any corporate integrity agreements, monitoring agreements, consent decrees, or similar agreements with Regulatory Agencies.
• No federal or state whistleblower actions have been filed against SpringWorks.
• SpringWorks will promptly notify Parent of any litigation instituted or threatened against the Company or its directors/officers relating to the Merger and will cooperate in defense and settlement.

Stakeholder Impact

• Shareholders: Will receive $47.00 in cash per share, providing immediate value and liquidity. They will cease to be stockholders of SpringWorks and will not participate in its future performance. U.S. Holders will incur U.S. federal income tax consequences. Dissenting shareholders have appraisal rights under Delaware law.
• Employees: Continuing employees will receive comparable base salary/wages and target cash incentive compensation for one year post-merger. Employee benefits (excluding equity-based compensation, severance, nonqualified deferred compensation, retiree health benefits, and defined benefit pension plan benefits) will be substantially comparable in the aggregate. Severance benefits will be no less favorable. Unvested equity awards will convert to cash-based awards with continued vesting, with 50% acceleration on the nine-month anniversary of closing. Certain executive officers have double-trigger severance entitlements.
• Customers, Suppliers, and Partners: The announcement, pendency, or consummation of the Merger could lead to adverse changes in relationships with these third parties.
• Creditors: All claims, debts, liabilities, and obligations of SpringWorks will become those of the Surviving Corporation, which will be a wholly owned subsidiary of Merck KGaA.

Next Steps

• SpringWorks will hold a Special Meeting of Stockholders on June 26, 2025, to vote on the Merger Proposal, Adjournment Proposal, and Compensation Proposal.
• The Merger is anticipated to be consummated in the second half of 2025, subject to stockholder approval and regulatory clearances (HSR Act waiting period expiration/termination, German antitrust approval).
• Following the Effective Time, SpringWorks' shares will cease trading on Nasdaq and be delisted, and the Company will be deregistered under the Exchange Act.
• SpringWorks will take actions to terminate its 401(k) plan effective immediately prior to the Effective Time, if requested by Parent.
• Parent will designate a tax-qualified defined contribution retirement plan to cover Continuing Employees and accept rollovers from SpringWorks' 401(k) plan.
• SpringWorks will ensure all known product liability claims are noticed to its existing product liability insurance coverage provider prior to the Effective Time.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Merger, Acquisition, Oncology, Rare Diseases, Cancer, Desmoid Tumors, Neurofibromatosis Type 1, OGSIVEO, Nirogacestat, GOMEKLI, Mirdametinib, SEC Filing, Proxy Statement, SWTX, Merck KGaA, Healthcare, Pharmaceuticals